

## Dose-response benefits of breastfeeding<sup>a</sup> from the American Academy of Pediatrics

<b>Condition</b>	<b>% lower risk<sup>b</sup></b>	<b>Breastfeeding</b>	<b>Comments</b>	<b>OR<sup>c</sup></b>	<b>95% CI</b>
Otitis media	<b>23</b>	Any	-	<b>0.77</b>	<b>0.64-0.91</b>
Otitis media	<b>50</b>	≥ 3 or 6 mo	Exclusive BF	<b>0.50</b>	<b>0.36-0.70</b>
Recurrent otitis media	<b>77</b>	Exclusive BF ≥6 mo <sup>d</sup>	Compared with BF 4 to < 6 mo <sup>d</sup>	<b>1.95</b>	<b>1.06-3.59</b>
Upper respiratory tract infection	<b>63</b>	>6 mo	Exclusive BF	<b>0.30</b>	<b>0.18-0.74</b>
Lower respiratory tract infection	<b>72</b>	≥4 mo	Exclusive BF	<b>0.28</b>	<b>0.14-0.54</b>
Lower respiratory tract infection	<b>77</b>	Exclusive BF ≥6 mo <sup>d</sup>	Compared with BF 4 to < 6 mo <sup>d</sup>	<b>4.27</b>	<b>1.27-14.35</b>
Asthma	<b>40</b>	≥ 3 mo	Atopic family history	<b>0.60</b>	<b>0.43-0.82</b>
Asthma	<b>26</b>	≥ 3 mo	No atopic family history	<b>0.74</b>	<b>0.6-0.92</b>
RSV bronchiolitis	<b>74</b>	>4 mo	-	<b>0.26</b>	<b>0.074-0.9</b>
NEC	<b>77</b>	NICU stay	Preterm infants Exclusive HM	<b>0.23</b>	<b>0.51-0.94</b>
Atopic dermatitis	<b>27</b>	>3 mo	Exclusive BF negative family history	<b>0.84</b>	<b>0.59-1.19</b>
Atopic dermatitis	<b>42</b>	>3 mo	Exclusive BF positive family history	<b>0.58</b>	<b>0.41-0.92</b>
Gastroenteritis	<b>64</b>	Any	-	<b>0.36</b>	<b>0.32-0.40</b>
Inflammatory bowel disease	<b>31</b>	Any	-	<b>0.69</b>	<b>0.51-0.94</b>
Obesity	<b>24</b>	Any	MONTÉRÉGIE -	<b>0.76</b>	<b>0.67-0.86</b>
Celiac disease	<b>52</b>	>2 mo	Gluten exposure when BF	<b>0.48</b>	<b>0.40-0.89</b>
Type 1 diabetes	<b>30</b>	>3 mo	Exclusive BF	<b>0.71</b>	<b>0.54-0.93</b>
Type 2 diabetes	<b>40</b>	Any	-	<b>0.61</b>	<b>0.44-0.85</b>
Leukemia (ALL)	<b>20</b>	>6 mo	-	<b>0.80</b>	<b>0.71-0.91</b>
Leukemia (AML)	<b>15</b>	>6 mo	-	<b>0.85</b>	<b>0.73-0.98</b>
SIDS	<b>36</b>	Any >1 mo	-	<b>0.64</b>	<b>0.57-0.81</b>

ALL. Acute lymphocytic leukemia : AML. Acute myelogenous leukemia: BF. Breastfeeding : HM. Human milk : RSV. Respiratory syncytial virus.  
a pooled data

b % lower risk refers to lower risk while BF compared with feeding commercial infant formula or referent group specified.

c OR expressed as increase risk for commercial formula feeding.

d Referent group is exclusive BF ≥6 months

Tableau adapté de : AMERICAN ACADEMY OF PEDIATRICS (2012). Policy statement : Breastfeeding and the Use of Human Milk, section on breastfeeding. Pediatrics 129 (3); e827. [En ligne] <http://pediatrics.aappublications.org/content/129/3/e827.full.pdf+html>.